NanoViricides (NYSE-A:NNVC), a specialist in broad-spectrum antiviral medicines, highlighted the efficacy of its lead drug, NV-387 against a range of viruses in animal models as it prepares to begin its first Phase II trials.
NV-387 has successfully completed Phase I clinical trials in healthy subjects, demonstrating excellent safety and tolerability with no dropouts or adverse events.
The company is preparing for a first Phase II study, targeting RSV, particularly in pediatric patients where there is a significant unmet need.
The projected market size for RSV is estimated at $2.60 billion in 2024, growing to $4.30 billion in three years.
NV-387 has cured lethal lung respiratory syncytial virus (RSV) infection in animal modes, also outperforming approved drugs for Influenza, besting Remdesivir against lethal coronavirus infection, and matching the activity of TPOXX against poxvirus.
"We believe that this ultra-broad-spectrum antiviral activity of NV-387 became possible because NV-387 is designed to mimic an invariant host feature that over 90% human pathogenic viruses employ for attachment and infection," the company stated.
NanoViricides (NYSE-A:NNVC) is also developing NV-HHV-1, a drug for treating herpesvirus infections such as shingles, chickenpox and HSV.
The company has demonstrated the capability to manufacture its drug candidates at a multi-Kg scale in a cGMP-compliant facility.
NanoViricides (NYSE-A:NNVC) holds exclusive licenses for various antiviral drugs, including treatments for HIV, hepatitis B and C, rabies, herpes, influenza, ebola, and dengue fever.
The company aims to continue expanding its pipeline and advancing its drug candidates through clinical trials.